IDEAYA Biosciences Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDEAYA Biosciences stock.
View analyst ratings for IDEAYA Biosciences or view top-rated stocks.

Wall Street analysts have given IDEAYA Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IDEAYA Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

IDEAYA Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for IDEAYA Biosciences.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its quarterly earnings data on Monday, August, 9th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.26. The business earned $8.76 million during the quarter, compared to analyst estimates of $10.04 million. IDEAYA Biosciences had a negative net margin of 84.49% and a negative trailing twelve-month return on equity of 13.85%.
View IDEAYA Biosciences' earnings history.

IDEAYA Biosciences' stock was trading at $4.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IDYA shares have increased by 453.8% and is now trading at $26.86.
View which stocks have been most impacted by COVID-19.

6 brokers have issued 1 year price targets for IDEAYA Biosciences' stock. Their forecasts range from $28.00 to $38.00. On average, they expect IDEAYA Biosciences' stock price to reach $32.43 in the next year. This suggests a possible upside of 20.7% from the stock's current price.
View analysts' price targets for IDEAYA Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to IDEAYA Biosciences include Hypera (HYPMY), Reata Pharmaceuticals (RETA), Turning Point Therapeutics (TPTX), Arena Pharmaceuticals (ARNA), Galapagos (GLPG), Karuna Therapeutics (KRTX), Prothena (PRTA), 23andMe (ME), Zentalis Pharmaceuticals (ZNTL), ALX Oncology (ALXO), Cryoport (CYRX), Insmed (INSM), Emergent BioSolutions (EBS), Nektar Therapeutics (NKTR) and PTC Therapeutics (PTCT).
View all of IDYA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), The Boeing (BA), Xeris Pharmaceuticals (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

(IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

IDEAYA Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RTW Investments LP (8.51%), BlackRock Inc. (7.91%), Federated Hermes Inc. (4.26%), Price T Rowe Associates Inc. MD (3.41%), Vanguard Group Inc. (3.25%) and Point72 Asset Management L.P. (1.80%). Company insiders that own IDEAYA Biosciences stock include Bvf Partners L P/Il, Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone, Value Fund L P Biotechnology and Ventures Iv LP 5Am.
View institutional ownership trends for IDEAYA Biosciences.

IDYA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Woodline Partners LP, EAM Global Investors LLC, EAM Investors LLC, JPMorgan Chase & Co., AQR Capital Management LLC, BNP Paribas Arbitrage SA, and Cubist Systematic Strategies LLC. Company insiders that have sold IDEAYA Biosciences company stock in the last year include Jason Throne, Mark Lackner, Michael P Dillon, Paul A Stone, and Ventures Iv LP 5Am.
View insider buying and selling activity for IDEAYA Biosciences or view top insider-selling stocks.

IDYA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., RTW Investments LP, Price T Rowe Associates Inc. MD, AXA S.A., Vanguard Group Inc., Sphera Funds Management LTD., Federated Hermes Inc., and State Street Corp. Company insiders that have bought IDEAYA Biosciences stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for IDEAYA Biosciences or or view top insider-buying stocks.

Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IDYA stock can currently be purchased for approximately $26.86.

IDEAYA Biosciences has a market capitalization of $1.03 billion and generates $19.54 million in revenue each year. The company earns $-34,490,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

IDEAYA Biosciences employs 62 workers across the globe.

The official website for IDEAYA Biosciences is www.ideayabio.com.

IDEAYA Biosciences is headquartered at 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080.

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 443-6209 or via email at [email protected].